BRKR
Bruker Corporation
September 16, 2026 · market open
- Rarity
- 1.69
- Peak move
- +10.59%
- Float cap
- $5.7B
Bruker Corporation develops, manufactures, and distributes high-performance scientific instruments and analytical and diagnostic solutions. Its products enable customers to explore life and materials at microscopic, molecular, and cellular levels, serving customers in life science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 1 from SEC or newswire · 0 timed with the moveexecutive_remarkAt Morgan Stanley's 24th Annual Global Healthcare Conference, Bruker CEO Frank Laukien and CFO Gerald Herman said the company may return to long-term growth by 2028, cited semiconductor metrology at roughly $500M primary metrology plus about $200M capacity/advanced-packaging, HBM and AI as 2026 drivers, and non-US academic and government orders up over 20%.
insider_saleBruker EVP and Bruker Nano President Mark R. Munch filed a Form 144 notice on September 15, 2026 to sell 2,000 common shares at $52.87 for about $105,740 under a Rule 10b5-1 plan, acquired through a same-day stock option exercise of 4,000 shares at $22.19, with sale through Morgan Stanley Smith Barney, following prior sales of 2,000 shares each on August 14 and July 15, 2026.
insider_saleBruker Corporation filed SEC Form 144 on September 15, 2026 reporting a proposed sale of securities by an insider holding shares in the company.
analyst_ratingMarketBeat reported Bruker consensus rating of Hold across 14 brokerages with an average 12-month price target of $57.00, while Guggenheim raised its target to $70 with a Buy rating.
policy_changeThe White House announced that from September 15 it will impose a 25% ad valorem import tariff on certain imported semiconductors, semiconductor manufacturing equipment and derivative products, citing national security.